- Global Pharma News & Resources

Global Valvular Heart Disease Treatment Market to Record an Impressive Growth Rate during the Forecast Period 2018 to 2025

A new research report published by Fior Markets with the title Valvular Heart Disease Treatment Market by Disease (Aortic Valve, Mitral Valve, Others), Diagnosis, Treatment, End User, Regions, and Global Forecast 2018-2025.

As per the report, The global valvular heart disease treatment market is expected to grow from USD XX.XX Million in 2017 to USD XX.XX Million by 2025, at a CAGR of X.XX% during the forecast period from 2018-2025. The North America region emerged as the leader in the global valvular heart disease treatment market with a 44.91% share of revenue in 2017.


Major players in the global valvular heart disease treatment market are Abbott Laboratories, B. Braun Melsungen AG, Boston Scientific Corp., Medtronic, PLC, CryoLife Inc., Edwards Lifesciences Corporation, LivaNova PLC, Neovasc Inc., Micro Interventional Devices, Inc., Symetis SA, Jenavalve Technology, Inc., TTK Healthcare Limited, Colibri Heart Valve, LLC, Lepu Medical Technology Co., Ltd., Braile Biomédica, and among others. Newborns and infants, with congenital valve defects who may be too small to use currently-marketed heart valves. Thus to fulfil this unmet demand US FDA has approved the Masters Series Mechanical Heart Valve. These new heart valves are small enough to be used in newborn pediatric patients to treat heart defects.

Disease segment is divided into aortic valve disorder, mitral valve disorder, pulmonary valve disorder and others. Due to growing prevalence of aortic stenosis and aortic valve regurgitation disorders the aortic valve disorder segment emerged as the leading segment with a 41.37% share of market revenue in 2017. Mitral valve Mitral valve segment also accounted for a significant share of the global valvular heart disease treatment market in 2017. Diagnosis segment is categorized into cardiac catheterization, electrocardiogram (ECG), chest x-ray, stress testing and others. Due to property of electrocardiogram (ECG) for being easy to use and cost effective, the electrocardiogram (ECG) segment emerged as the largest diagnosis segment with a 34.53% share of market revenue 2017. Cardiac catheterization segment is anticipated to grow at an accelerated CAGR of X.XX% over the forecast period. Treatment segment is fragmented into medication and surgery. Surgery is further divided into valve repair and valve replacement. The valvular heart diseases can be treated by medication such as Antithrombotic (clot-preventing) medications such as aspirin or ticlopidine. Surgery are performed using endovascular techniques which are minimally invasive and with help of transcatheter valves, and other devices and mechanical circulatory support. End user is segmented into hospital & clinics, ambulatory surgical centers and research institutes. The hospitals & clinics segment led the global valvular heart disease treatment market with a 56.52% share of market revenue in 2017. Whereas the research institutes segment is projected to grow at the fastest pace over the forecast period.

Even though the factors such as rising geriatric population, increase in prevalence of heart valve disease are driving the global valvular heart disease treatment market, the high cost of treatment as well as shortage of skilled surgeons are expected to hold back the market growth.


About the report: 
The global valvular heart disease treatment market is analysed on the basis of value (USD Billion), volume (K Units), export (K Units), and import (K Units). All the segments have been analyzed on global, regional and country basis. The study includes an analysis of more than 30 countries for each segment. The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The study includes porter’s five forces model, attractiveness analysis, raw material analysis, and competitor position grid analysis.

Customization of the Report:
The report can be customized as per client requirements. For further queries, you can contact us on or +1-201-465-4211. Our executives will be pleased to understand your requirements and offer you the best-suited reports.

Contact Us
Mark Stone
Phone: +1-201-465-4211

This content has been distributed via CDN Newswire press release distribution service. For press release enquires please mail us at

Editor Details

  • Company:
    • CDN Newswire
Last Updated: 10-Jul-2020